Dr. Christopher J. Schaber outlines strategies for navigating constrained funding environment  Soligenix (NASDAQ: SNGX) CEO Dr. Christopher J. Schaber emphasized the importance of capital discipline in a Pharmaphorum analysis examining how biotech companies can succeed in today’s constrained funding environment, where even late-stage programs may struggle to secure investment. The article notes that strong science alone is no longer sufficient, […]

Solana and the rest of the crypto market has gone through many ups and downs over the last few years. The current volatility and pressures in the market, encouraged by ongoing geopolitical factors, have led to attractive entry prices for those looking to get involved with crypto. Current prices, along with growing concern about the […]

Channelchek, a Noble Financial Group platform, highlights a changing investment landscape in 2025, where capital is increasingly rotating toward differentiated growth opportunities beyond crowded sectors. Within this environment, Enhanced Group Inc.—an emerging sports, media, and consumer health company—is pursuing a public market debut through a proposed business combination with A Paradise Acquisition Corp. (NASDAQ: APAD), positioning itself within […]

NRx Pharmaceuticals (NASDAQ: NRXP) welcomed a newly signed Executive Order aimed at accelerating medical treatments for serious mental illness, including expanded access to psychedelic therapies and faster regulatory pathways. The order directs the FDA to issue priority vouchers for qualifying breakthrough therapies and encourages broader use of clinical trial data and real-world evidence, aligning with NRx’s […]

This article has been disseminated on behalf of Planet Ventures Inc. and may include paid advertising.  Planet Ventures (CSE: PXI) (OTC Pink: PNXPF) (FSE: P6U) announced it has adopted a Disclosure, Confidentiality and Insider Trading Policy to strengthen compliance with Canadian securities laws, prevent selective disclosure and ensure proper handling of material information, while also updating its Investment Policy to […]

By Christopher J. Schaber, chairman, president, and CEO, Soligenix; published via Clinical Leader  Soligenix (NASDAQ: SNGX) is emphasizing the strategic importance of patient-centric drug development, as outlined by CEO Christopher J. Schaber in a Clinical Leader guest column, which explores how reformulating therapies can improve access, adherence, and real-world viability. Drawing on the company’s experience with SGX945, Schaber explains that […]

Beeline Holdings (NASDAQ: BLNE), a fast-growing digital mortgage platform offering a quicker and easier path to homeownership, is advancing its strategy to embed mortgage and title services directly into digital real estate platforms, with a newly announced partnership with Structured Real Estate Group (“SRG”). The agreement, detailed in a company press release, positions Beeline’s technology […]

Safe Pro Group (NASDAQ: SPAI) reported continued execution of its share repurchase program, with 400,000 shares repurchased as of April 17, 2026, representing approximately 3.5% of its public float under a $3.0 million authorization approved in December 2025. The company funded repurchases through operating cash flow and its strong balance sheet, which included $16.7 million in cash and no […]

Amid increased demand for advanced collision-avoidance systems as rail networks grow more complex, Rail Vision’s (NASDAQ: RVSN) artificial-intelligence (“AI”)-powered electro-optical sensors are emerging as a direct technological response. “Rail Vision develops vision-based detection systems designed to improve railway safety and operational performance, offering real-time obstacle detection and situational awareness that align closely with evolving safety priorities across the […]

Boca Raton, Florida-based LIXTE Biotechnology Holdings (NASDAQ: LIXT) spent 2025 expanding its presence across multiple segments of oncology innovation. “The company is best known for its clinical-stage pharmaceutical pipeline built around LB-100, a first-in-class inhibitor of protein phosphatase 2A (‘PP2A’),” a recent article reads. “Rather than replacing established cancer therapies, LB-100 is designed to enhance their effectiveness. […]

Artificial intelligence-powered cardiovascular medicine company Cardio Diagnostics Holdings (NASDAQ: CDIO) was featured in a recent article that discussed its focus on cardiovascular disease prevention, detection, and management. The publication reads, “The company’s approach is centered on advancing how cardiovascular disease is addressed by moving beyond traditional methods that rely on indirect or generalized indicators… At the core of […]

Recognition from global regulatory authorities can serve as a powerful validation of a therapy’s potential, particularly in the rare disease space where development challenges are significant and patient needs are urgent. Soligenix (NASDAQ: SNGX) has secured that type of validation, as the European Commission granted orphan drug designation to its investigational therapy SGX945 for the […]